AASLD updates its MASH practice guidance for semaglutide

The American Association for the Study of Liver Diseases (AASLD) published updated practice guidance in November 2025 explaining how clinicians should select, treat, and monitor adults with metabolic dysfunction–associated steatohepatitis (MASH) who have moderate-to-advanced liver scarring using semaglutide, sold as Wegovy ^[1]. The update follows the drug's accelerated FDA approval on August 15, 2025, for MASH with fibrosis stages 2 to 3 ^[1].

That approval rested on the first 800 participants in the ongoing phase 3 ESSENCE trial. After 72 weeks of weekly 2.4 mg semaglutide injections, 62.9% of patients had MASH resolve without their fibrosis getting worse, compared with 34.3% on placebo (p<0.001) ^[1]. Separately, 36.8% of treated patients had their fibrosis improve by at least one stage without their MASH worsening, versus 22.4% on placebo (p<0.001) ^[1]. Full FDA approval depends on the trial confirming lasting clinical benefit, with results not expected until 2028 or later ^[1].

Because a liver biopsy is impractical for most people, AASLD's guidance leans on non-invasive tests to identify who is a reasonable candidate. It recommends liver stiffness readings by transient elastography (VCTE) of 8–15 kPa, magnetic resonance elastography (MRE) of 3.1–4.4 kPa, or enhanced liver fibrosis (ELF) scores of 9.2–10.5 as the target range, rather than routine biopsy ^[1]. For results just above those ranges — VCTE 15–20 kPa, MRE 4.4–5 kPa, or ELF 10.5–11.3 — the guidance calls for an individualized decision after ruling out cirrhosis with a confirmatory test, imaging, or a platelet count check ^[1]. Semaglutide is not approved for people who already have MASH cirrhosis, defined by higher stiffness values or signs of portal hypertension ^[1].

On safety, the guidance notes semaglutide showed no discontinuations tied to liver enzyme elevations in ESSENCE, and it says routine liver blood panels are needed only when clinically indicated ^[1]. The most common side effects were gastrointestinal — nausea, diarrhea, constipation, and vomiting — usually mild and temporary ^[1]. AASLD also flags rarer but serious risks to watch for, including dehydration-related kidney injury, gallbladder disease, pancreatitis, thyroid C-cell tumors, worsening of diabetic eye disease, and loss of lean muscle mass ^[1]. Combining semaglutide with resmetirom, another MASH drug, has not been studied ^[1].

Why it matters for patients

This guidance does not change the FDA label, but it gives doctors a practical framework for deciding who might benefit from semaglutide for liver scarring specifically, separate from its established uses for weight management and cardiovascular risk reduction ^[1]. For patients with MASH and moderate fibrosis, it means eligibility is likely to be judged using blood tests or elastography scans rather than a liver biopsy, and that the FIB-4 blood test — which excludes advanced fibrosis in 99% of patients when the score is below 1.3 — may be a first screening step ^[1]. The guidance also stresses that lifestyle changes remain part of MASH management alongside any medication, and that there is currently no reliable way to predict, from tests alone, which individual patients will respond best ^[1].

What happens next

Final FDA approval for the MASH fibrosis indication is contingent on longer-term data from the full ESSENCE trial, which AASLD says are not expected before 2028 ^[1]. Until then, semaglutide's use for MASH with fibrosis carries an accelerated approval status, meaning the benefit seen so far must still be confirmed in the completed study ^[1].